close read more
Press release

Servier partners with BioLabs Global to open an incubator in Paris-Saclay for early stage life science companies


Servier partners with BioLabs Global to open an incubator in Paris-Saclay for early stage life science companies

A unique hub for innovation in health sciences


Suresnes, France and Cambridge MA, USA, June 23, 2021 – Servier, a global independent pharmaceutical Group, and Biolabs Global, (“BioLabs”) a developer and  operator of premium co-working laboratories in the US and Europe, announce today that they have entered into a services agreement to manage Servier’s start-up incubator located in the future Servier R&D Institute in Paris-Saclay due to open in 2023.

The start-up co-working laboratory created by Servier within its Research and Development Institute in Paris-Saclay aims to be a major player in therapeutic innovation. The unprecedented synergy between the dynamism of young, promising companies in the healthcare sector and Servier’s pharmaceutical expertise offers unique conditions for developing and accelerating drug discovery, both in France and worldwide.

“The start-up incubator encourages a new level of knowledge sharing. Networked innovation without barriers is crucial for serving patients’ unmet needs even more effectively and rapidly. Agile methods to accelerate R&D programs are based on synergies and teamwork,” comments Christophe Thurieau, Executive Director of Servier Research.

This incubator inside the Servier Research and Development Institute will offer a unique combination of space and services in France, and represents Servier’s ambition to renew itself and its new approach to R&D. It will allow start-ups to have their independence regarding Servier, while being close-by and benefiting from Servier’s scientific and technological expertise.


A place for innovation

Spanning 1,850 m2, the co-working laboratory has been designed with a capacity for, approximately 20 companies with space for over 100 scientists. The beautifully designed spaces will offer fully equipped and permitted premium shared and private laboratory spaces, conference facilities, central café and adjacent office and hot desks for the start-up companies. Residents will have access to the central Servier support spaces and core facilities and benefit from an easy to use e-procurement solution and integrated biohazard and chemical waste management.  Additionally, residents are connected to fellow entrepreneurs from around the globe and to sponsor companies from many industries through the BioLabs network. Participants join this fertile ecosystem on their first day at the lab.

Admission to the Center will be through an application and selection process managed by BioLabs. The application process will be opened in Summer 2022. To promote and facilitate interactions prior to opening, Servier and BioLabs are offering regular webinars, Masterclasses and mentoring programs. The first Masterclass mentoring workshop for start-ups will take place on November 2021 in Boston.


A recognized player with international experience to offer a unique range of services

Servier will partner with BioLabs to operate and manage this tailor-made space. BioLabs is experienced and recognized in health/life sciences at a global level. Both companies are interested and highly motivated to support the acceleration of R&D projects.

“Launching this site in collaboration with Servier is an extraordinary opportunity for us. Servier has been a valuable partner in the US and has shown that they have the vision and enthusiasm to support entrepreneurs at this very early stage. This commitment to health science innovation matches our own mission and values. We look forward to supporting the community alongside Servier with webinars, masterclasses and mentoring prior to the launch and welcoming quality start-ups in 2023,” said Johannes Fruehauf, Founder, President & CEO of Biolabs.

BioLabs will oversee the day-to-day management of the site, the provision of supplies, services and equipment, the practical support and events and programming specific to the interests of life science start-ups. They will also establish contacts with industry leaders and the entrepreneurial ecosystem at large, in Saclay and throughout France and beyond.


Paris-Saclay, an unprecedented location to bio-innovate in France

With 15% of national research, 40% of public and private research jobs in Île-de-France with the jewels of French academic and private research, the scientific and technological cluster of Paris-Saclay is among the eight most powerful innovation hubs in the world. This density and variety of resources makes Paris-Saclay unique. It gives Paris-Saclay all the advantages of one of the most attractive innovation clusters for investors, innovators and entrepreneurs from all over the world.


The Paris-Saclay cluster offers a promising array of potential future partners.

“Combining this unique place for health start-ups to grow and learn from experienced professionals with the vibrant ecosystem of Paris Saclay makes a unique opportunity to support therapeutic and technology innovation and improve the life of patients,” concludes Olivier Nosjean, Head of Global Open Innovation and Scientific Affairs at Servier.


About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2020, Servier employs 22,500 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities, from research to support beyond the pill.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neurosciences and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies More information: servier.com


Servier Media Relations contacts:

Sonia Marques               : presse@servier.com – Tel. +33 (0)1 55 72 40 21 / + 33 (0)7 84 28 76 13
Jean-Clément Vergeau    : presse@servier.com – Tel. +33 (0)1 55 72 46 16 / +33 (0)6 79 56 75 96


About BioLabs

BioLabs Global is a membership-based network of shared lab facilities designed exclusively for high-potential, early-stage life science companies located in the key biotech innovation hot spots. We offer co-working environments that pair premium, fully equipped and supported lab and office space with unparalleled access to capital and industry partners. This fertile, supportive ecosystem allows nascent companies to focus on innovation, not startup operations, so they can realize their scientific potential quickly and achieve business success. Companies can start with a single bench and scale up as they grow. Headquartered in Cambridge, MA USA, BioLabs has a growing network of labs across the US and is actively expanding into new domestic and international geographies.


BioLabs Media Relations Contacts:

March Communications


Direct 01-617-960-8895  allison@marchcomms.com



Press release

Last press release

Press release
Servier appoints Angelo Paci as Oncology & Immuno-Oncology Program Leader
Press release
Servier appoints Nicolas Lévy as Chief Scientist Rare Diseases
Press release
Appointment of Walid S. Kamoun, PhD. MSc., Global Head of Servier R&D Oncology